Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of BIV-201 for the treatment of ascites due to liver cirrhosis.

Trial Profile

A study of BIV-201 for the treatment of ascites due to liver cirrhosis.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Terlipressin (Primary)
  • Indications Ascites
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Feb 2017 According to a BioVie Inc. media release, the company expects to initiate this trial in the first half of 2017 after approval of IND by the US FDA.
    • 22 Feb 2017 According to a BioVie Inc. media release, the company has submitted a complete response to the US FDA addressing the issues identified in the IND clinical hold letter received by the company in January 2017.
    • 29 Nov 2016 According to a BioVie Inc media release, company announced the submission of an Investigational New Drug (IND) application for new drug candidate BIV201 to the US Food and Drug Administration (FDA).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top